Acadia Pharmaceuticals to Announce Third Quarter Financial Results on November 6, 2024
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) has announced that it will release its third quarter financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. The company's management team will host a conference call and webcast at 4:30 p.m. Eastern Time on the same day to discuss the results and operations.
Investors can access the conference call through Acadia's website or by registering for the call to receive dial-in details. The call recording will be archived on the company's website until December 6, 2024.
Acadia is known for developing the first FDA-approved drug for hallucinations and delusions associated with Parkinson's disease psychosis, as well as the first approved drug in the U.S. and Canada for Rett syndrome treatment. The company's clinical-stage efforts focus on Prader-Willi syndrome, Alzheimer's disease psychosis, and other neuropsychiatric symptoms in CNS disorders.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre mercoledì 6 novembre 2024, dopo la chiusura dei mercati finanziari statunitensi. Il team di gestione dell'azienda ospiterà una chiamata in conferenza e un webcast alle 16:30, ora orientale, lo stesso giorno per discutere i risultati e le operazioni.
Gli investitori possono accedere alla chiamata in conferenza tramite il sito web di Acadia o registrandosi per la chiamata per ricevere i dettagli di accesso. La registrazione della chiamata sarà archiviata sul sito web dell'azienda fino al 6 dicembre 2024.
Acadia è nota per aver sviluppato il primo farmaco approvato dalla FDA per le allucinazioni e le delusioni associate alla psicosi di Parkinson, così come il primo farmaco approvato negli Stati Uniti e in Canada per il trattamento della sindrome di Rett. Gli sforzi clinici dell'azienda si concentrano sulla sindrome di Prader-Willi, psicosi di Alzheimer e altri sintomi neuropsichiatrici nei disturbi del SNC.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) ha anunciado que publicará sus resultados financieros del tercer trimestre el miércoles 6 de noviembre de 2024, después del cierre de los mercados financieros en EE. UU. El equipo directivo de la empresa llevará a cabo una llamada de conferencia y un webcast a las 4:30 p.m., hora del Este, el mismo día para discutir los resultados y las operaciones.
Los inversores pueden acceder a la llamada de conferencia a través de la página web de Acadia o registrándose para recibir detalles de conexión. La grabación de la llamada se archivará en la página web de la empresa hasta el 6 de diciembre de 2024.
Acadia es conocida por desarrollar el primer medicamento aprobado por la FDA para las alucinaciones y delirios asociados con la psicosis de Parkinson, así como el primer medicamento aprobado en EE. UU. y Canadá para el tratamiento del síndrome de Rett. Los esfuerzos clínicos de la empresa se centran en el síndrome de Prader-Willi, la psicosis del Alzheimer y otros síntomas neuropsiquiátricos en trastornos del SNC.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD)는 2024년 11월 6일 수요일 미국 금융 시장이 마감된 후 3분기 재무 결과를 발표할 예정임을 발표했습니다. 같은 날 동부 표준시로 오후 4시 30분에 회사의 경영진 팀이 결과와 운영에 대해 논의하기 위한 컨퍼런스 콜 및 웹캐스트를 주최할 것입니다.
투자자는 Acadia의 웹사이트를 통해 컨퍼런스 콜에 참여하거나 전화를 위한 등록을 통해 다이얼인 정보를 받을 수 있습니다. 통화 녹음은 2024년 12월 6일까지 회사 웹사이트에 보관됩니다.
Acadia는 파킨슨병 정신증과 관련된 환각 및 망상에 대해 FDA 승인을 받은 첫 번째 약을 개발한 것으로 알려져 있으며, Rett 증후군 치료를 위한 미국 및 캐나다에서 승인된 첫 번째 약입니다. 회사의 임상 단계 노력은 프라더-윌리 증후군, 알츠하이머병 정신증 및 CNS 장애에서의 기타 신경정신적 증상에 집중하고 있습니다.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) a annoncé qu'elle publiera ses résultats financiers du troisième trimestre le mercredi 6 novembre 2024, après la fermeture des marchés financiers américains. L'équipe de direction de l'entreprise animera une conférence téléphonique et un webcast à 16h30, heure de l'Est, le même jour pour discuter des résultats et des opérations.
Les investisseurs peuvent accéder à la conférence téléphonique par le biais du site web d'Acadia ou en s'inscrivant à l'appel pour recevoir les détails de connexion. L'enregistrement de l'appel sera archivé sur le site web de l'entreprise jusqu'au 6 décembre 2024.
Acadia est connue pour avoir développé le premier médicament approuvé par la FDA pour les hallucinations et les délires associés à la psychose de Parkinson, ainsi que le premier médicament approuvé aux États-Unis et au Canada pour le traitement du syndrome de Rett. Les efforts cliniques de l'entreprise se concentrent sur le syndrome de Prader-Willi, la psychose d'Alzheimer et d'autres symptômes neuropsychiatriques dans les troubles du SNC.
Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) hat angekündigt, dass es seine Finanzergebnisse für das dritte Quartal am Mittwoch, dem 6. November 2024, nach Marktschluss der US-Finanzmärkte veröffentlichen wird. Das Managementteam des Unternehmens wird am selben Tag um 16:30 Uhr Eastern Time eine Telefonkonferenz und einen Webcast abhalten, um die Ergebnisse und die Operationen zu besprechen.
Investoren können auf die Telefonkonferenz über die Website von Acadia zugreifen oder sich für den Anruf registrieren, um die Einwahldaten zu erhalten. Die Aufzeichnung des Anrufs wird bis zum 6. Dezember 2024 auf der Unternehmenswebsite archiviert.
Acadia ist bekannt für die Entwicklung des ersten von der FDA zugelassenen Medikaments gegen Halluzinationen und Wahnvorstellungen im Zusammenhang mit der Parkinson-Krankheit sowie des ersten in den USA und Kanada zugelassenen Medikaments zur Behandlung des Rett-Syndroms. Die klinischen Bemühungen des Unternehmens konzentrieren sich auf das Prader-Willi-Syndrom, die Psychose bei Alzheimer und andere neuropsychiatrische Symptome bei ZNS-Störungen.
- None.
- None.
Company to host conference call and webcast on Wednesday, November 6, 2024, at 4:30 p.m. Eastern Time
The conference call will be available on Acadia’s website, Acadia.com under the investors section and will be archived there until December 6, 2024. The conference call may also be accessed by registering for the call here. Once registered, participants will receive an email with the dial-in number and unique PIN number to use for accessing the call.
About Acadia Pharmaceuticals Inc.
Acadia is advancing breakthroughs in neuroscience to elevate life. Since our founding we have been working at the forefront of healthcare to bring vital solutions to people who need them most. We developed and commercialized the first and only FDA-approved drug to treat hallucinations and delusions associated with Parkinson’s disease psychosis and the first and only approved drug in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241017732118/en/
Investor Contact:
Acadia Pharmaceuticals Inc.
Al Kildani
(858) 261-2872
ir@acadia-pharm.com
Source: Acadia Pharmaceuticals Inc.
FAQ
When will Acadia Pharmaceuticals (ACAD) report its Q3 2024 financial results?
What time is Acadia Pharmaceuticals' (ACAD) Q3 2024 earnings call scheduled for?
How can investors access Acadia Pharmaceuticals' (ACAD) Q3 2024 earnings call?
Until what date will Acadia Pharmaceuticals' (ACAD) Q3 2024 earnings call be archived?
